autologous tumor cell vaccine-Barbara Ann Karmanos Cancer Institute-melanoma

An unnamed, investigational **autologous whole-tumor-cell therapeutic vaccine** evaluated by Barbara Ann Karmanos Cancer Institute for resected stage III or IV melanoma. The product was intended to use tumor cells derived from the individual patient as a source of patient-specific melanoma antigens and was administered in an immunotherapy program involving granulocyte-macrophage colony-stimulating factor, subsequent adoptive transfer of activated autologous T lymphocytes, and interleukin-2. No distinct INN, sponsor development code, trade name, standardized cell-processing specification, or defined tumor-antigen composition was identified for the vaccine itself.

Other names

autologous tumor cell vaccine